Versant funds TCR therapy biotech T-knife's $78M+ Series A to boost humanized T cell mice platform
Just a day after announcing the formation of a startup in Switzerland that will develop alternative TCR cell therapies, Versant is keeping its foot on the gas.
The multibillion dollar life sciences VC announced Thursday morning it is leading the Series A funding of T-knife, a German biotech that plans to use its proprietary humanized T cell receptor (HuTCR) mouse platform to treat solid tumors. T-knife raised about $78.4 million in the round and hopes to not only develop its own pipeline but also license out its mice for use by other companies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.